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Introduction
Terpenoids, widely distributed in medicinal herbs, fruits 
and vegetables, are derived from five carbon isoprene units 
and are classified into five structural categories, namely 
monoterpenoids, sesquiterpenoids, diterpenoids, triterpe-
noids and tetraterpenoids [1]. Terpenoids are considered to 
be promising candidates for cancer treatment and chemo-
prevention [1–3]. The anticancer action of terpenoids is 
based on their anti-inflammatory, anti-proliferative and pro-
apoptotic effects both in in vitro and in vivo models [1–4]. 
At the molecular level, anticancer potency of terpenoids is 
achieved by modulating numerous signaling cascades by 
changes in the activities of transcription factors, antiapop-
totic and pro-apoptotic proteins, protein kinases and cell 
cycle proteins [1, 4, 5]. Most terpenoids may induce cancer 
cell death by targeting apoptotic pathways, but also other 
modes of death have been postulated [5, 6].
In cancer cells, mutations that activate oncogenes or 
inactivate tumor suppressor genes may affect multiple 
signaling pathways that results in metabolic reprogram-
ming and altered bioenergetics [7, 8]. One of characteris-
tic features of cancer cell metabolism is aerobic glycolysis 
(Warburg effect), a shift from ATP generation through oxi-
dative phosphorylation to ATP generation through glyco-
lysis, even in the presence of oxygen [9]. Despite aerobic 
glycolysis is far less efficient than oxidative phosphoryla-
tion in terms of ATP generated per unit of glucose con-
sumed, enhanced uptake and utilization of glucose also 
support biosynthetic pathways (the synthesis of biomass 
and reducing equivalents) and maintain cancer cell redox 
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homeostasis thus promoting cell growth and proliferation 
[10–12]. Attenuation or inhibition of glycolysis has been 
considered as an attractive anticancer strategy [13, 14] that 
can be achieved by inhibition of the glycolytic enzymes 
hexokinase (HK), phosphofructokinase (PFK) and pyru-
vate kinase (PK), all of which regulate irreversible and 
rate-limiting steps in glycolysis. Thus, it seems reasonable 
to search for small molecules acting as metabolic inhibitors 
that would lead to inhibition of cancer cell proliferation and 
cell death.
In the present study, we have investigated the mecha-
nisms of anticancer activity of two pentacyclic triterpe-
noids, namely ursolic acid (UA) and betulinic acid (BA) 
against phenotypically distinct breast cancer cells MCF-7 
 (ER+,  PR+/−,  HER2−), MDA-MB-231  (ER−,  PR−,  HER2−) 
and SK-BR-3  (ER−,  PR−,  HER2+), especially we were 
interested if UA and BA may modulate glycolytic path-
way. UA and BA, when used at the concentrations of 5 
and 10  µM, caused p21-mediated G0/G1 cell cycle arrest 
and senescence that was accompanied by oxidative stress 
and DNA damage. Moreover, 20 µM UA was found to be a 
potent inducer of apoptosis that was achieved by targeting 
glycolytic pathway and autophagy in breast cancer cells.
Materials and methods
Reagents
The reagents used, if not otherwise mentioned, were pur-
chased from Sigma–Aldrich (Poland) and were of analyti-
cal grade. Ursolic acid (3β-hydroxy-12-ursen-28-ic acid, 
UA) and betulinic acid (3β-hydroxy-20(29)-lupaene-28-oic 
acid, BA) were dissolved in dimethyl sulfoxide (DMSO). 
DMSO concentrations did not exceed 0.1% and had no 
effect on parameters analyzed.
Cell culture
Human breast cancer cells MCF-7, MDA-MB-231 and 
SK-BR-3 were obtained from ATCC (Manassas, VA, 
USA). Cells (10,000  cells/cm2) were cultured at 37 °C 
in Dulbecco’s Modified Eagle’s Medium (DMEM) sup-
plemented with 10% fetal calf serum (FCS) and antibi-
otic and antimycotic mix solution (100  U/ml penicillin, 
0.1 mg/ml streptomycin and 0.25 μg/ml amphotericin B) in 
a humidified atmosphere in the presence of 5%  CO2 until 
they reached confluence. Typically, cells were passaged by 
trypsinization and maintained in DMEM. Normal human 
mammary epithelial cells (HMEC) were obtained from 
Lonza (Basel, Switzerland). Cells (10,000 cells/cm2) were 
cultured in Mammary Epithelial Growth Medium (MEGM) 
supplemented with BPE, hydrocortisone, hEGF, insulin 
and gentamicin/ amphotericin B according to manufactur-
er’s instructions.
MTT assay
UA and BA cytotoxicities were estimated using an MTT 
assay as described comprehensively elsewhere [15]. 
Briefly, cells of an initial concentration of 5000 cells per 
a well of 96-well plate were incubated with 2.5, 5, 10, 20, 
30 and 50 µM UA and BA for 24 h and metabolic activity 
(MTT test) was then analyzed. The concentrations of 5, 10 
and 20 µM UA and BA and 24 h treatment were selected 
for further analysis.
Cell cycle
After UA and BA treatments, the percentage of cells in the 
G0/G1, S and G2/M phases of cell cycle was assessed using 
Muse™ Cell Analyzer and Muse™ Cell Cycle Kit accord-
ing to the manufacturer’s instructions (Merck Millipore).
Senescence-associated β-galactosidase activity 
(SA-β-gal)
Cells were incubated with UA and BA for 24 h, and 7 days 
after UA and BA removal SA-β-gal activity was assayed 
[16].
Apoptosis
After UA and BA treatments, live, early apoptotic, late 
apoptotic and dead cells were assessed using Muse™ Cell 
Analyzer and both Muse™ Annexin V and Dead Cell 
Assay Kit and Muse™ Multi-caspase Assay Kit (Merck 
Millipore) as described elsewhere [17]. As a positive con-
trol of apoptosis induction, cells were treated for 30  min 
with 10  mM hydrogen peroxide (HP) [18]. UA- and BA-
mediated changes in mitochondrial membrane potential 
were evaluated using Muse™ Cell Analyzer and Muse™ 
Mitopotential Assay Kit (Merck Millipore) according to 
manufacturer’s instructions.
Autophagy
UA- and BA-mediated autophagy was measured using 
Muse™ Cell Analyzer and Muse™ Autophagy LC3-anti-
body based Kit (Merck Millipore). As a positive control, 
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cells were incubated in Earle’s Balanced Salt Solution 
(EBSS) at 37 °C for 6  h according to the manufacturer’s 
instructions. Autophagy induction ratio (test sample fluo-
rescence vs. control sample fluorescence) is presented.
Oxidative and nitrosative stress parameters
After UA and BA treatments, intracellular reactive oxy-
gen species (ROS), total and mitochondrial superoxide 
production were estimated using the fluorogenic probes a 
chloromethyl derivative of  H2DCF-DA (CM-H2DCF-DA), 
dihydroethidium and MitoSOX™ Red reagent, respec-
tively [15]. UA- and BA-mediated protein carbonylation 
was estimated with an OxyBlot™ Protein Oxidation Detec-
tion Kit (Merck Millipore) using the standard protocol 
according to the manufacturer’s instructions. UA- and BA-
induced changes in the levels of nitric oxide were evalu-
ated using Muse™ Cell Analyzer and Muse™ Nitric Oxide 
Kit (Merck Millipore). As a positive control of nitrosa-
tive stress, cells were treated for 5 min with a nitric oxide 
donor, namely 1 mM MAHMA NONOate (Cayman Chem-
ical Company, Ann Arbor, Michigan, USA) [19].
DNA damage and DNA damage response
DNA double strand breaks (DSBs) and DNA single strand 
breaks (SSBs) were assessed using neutral and alkaline 
single-cell microgel electrophoresis (comet assay), respec-
tively as described elsewhere [20]. The percentage of tail 
DNA was used as a parameter of DNA damage. The activa-
tion of ATM and H2AX was measured using Muse™ Cell 
Analyzer and Muse™ Multi-Color DNA Damage kit con-
taining a phospho-specific ATM (Ser1981)-PE and a phos-
pho-specific Histone H2AX-PECy5 conjugated antibodies 
(Merck Millipore). Percentage of negative cells (no DNA 
damage), percentage of ATM activated cells, percentage 
of H2AX activated cells and percentage of DNA double-
strand breaks (dual activation of both ATM and H2AX) 
were calculated using Muse™ Multi-Color DNA Damage 
software module and presented as dot plots. As a positive 
control of DNA damage, cells were treated for 24  h with 
10 µM etoposide.
Immunostaining
An immunostaining protocol was used as previously 
described [17]. Briefly, UA- and BA-treated cells were 
fixed and incubated with the primary antibody anti-53BP1 
(1:200) (Novus Biologicals) and a secondary antibody con-
jugated to Texas Red (1:1000) (Thermo Fisher Scientific). 
Quantitative analysis was conducted using In Cell Analyzer 
software (GE Healthcare). 53BP1 foci were calculated per 
nucleus.
Western blotting
Whole cell protein extracts were prepared according to 
Lewinska et al. [16]. Polyvinylidene difluoride (PVDF) mem-
branes were incubated with the primary antibodies anti-p21 
(1:100), anti-p53 (1:500), anti-p27 (1:200), anti-GLUT1 
(1:1000), anti-HK2 (1:200), anti-PKM2 (1:1000), anti-LDHA 
(1:1000), anti-phospho-AMPKα (Thr172) (1:750), anti-
AMPKα (1:1000), anti-phospho-AKT (Ser473) (1:1750), 
anti-AKT (1:1000) or anti-β-actin (1:1000) (Thermo Fisher 
Scientific, Santa Cruz, Abcam, Cell Signaling) and a second-
ary antibody conjugated to HRP (1:50,000, Sigma–Aldrich). 
The respective proteins were detected using a Clarity™ West-
ern ECL Blotting Substrate (BioRad) and a G:BOX imaging 
system (Syngene, Cambridge, UK) according to the manu-
facturer’s instructions. Densitometry measurements of the 
bands were performed using GelQuantNET software (http://
biochemlabsolutions.com/GelQuantNET.html). The data rep-
resent the relative density normalized to β-actin.
ATP and lactate levels
ATP and lactate levels were measured in UA- and BA-treated 
cells using ATP assay kit and lactate assay kit (Sigma), 
respectively, according to the manufacturer’s instructions. A 
total of  106 cells were taken for analysis. Intracellular ATP 
and lactate contents were calculated on the basis of a standard 
curve obtained for ATP and lactate solutions, respectively, 
and are presented in ng/µl.
MAPK activation
UA- and BA-mediated extracellular signal-regulated kinase 
1/2 (ERK1/2) activity was measured using Muse™ Cell 
Analyzer and Muse™ MAPK Activation Dual Detection 
Kit using two directly conjugated antibodies, a phospho-
specific anti-phospho-ERK1/2 (Thr202/Tyr204, Thr185/
Tyr187)-phycoerythrin and anti-ERK1/2-PECy5 conjugated 
antibody (Merck Millipore) according to the manufacturer’s 
instructions.
Statistical analysis
The results represent the mean ± SD from at least three inde-
pendent experiments. Alternatively, box and whisker plots 
with median, lowest and highest values were used. Statistical 
significance was assessed by 1-way ANOVA using GraphPad 






UA and BA cause G0/G1 cell cycle arrest in breast 
cancer cells
First, we have analyzed the effect of two pentacyclic triter-
penotids, namely ursolic acid (UA) and betulinic acid (BA) 
on breast cancer cell metabolic activity (Fig. 1a).
Both triterpenotids significantly affected breast cancer 
cell metabolic activity when used at the concentration as 
low as 2.5 µM and 24 h treatment (Fig. 1a). UA was found 
to be more toxic than BA and calculated  IC50 values were 
20.44, 22.9 and 14.58 µM for MCF-7, MDA-MB-231 and 
SK-BR-3 cells and UA treatment, and 29.02, 30.58 and 
24.47  µM for MCF-7, MDA-MB-231 and SK-BR-3 cells 
and BA treatment, respectively (Fig. 1a). Three concentra-
tions of UA and BA, namely 5, 10 and 20 µM were selected 
for further analysis (Fig.  1a). UA also affected the cell 
cycle of breast cancer cells more than BA (Fig.  1b). UA 
and BA (10 µM) promoted accumulation of cells in the G0/
G1 phase of the cell cycle (Fig. 1b). An increase of 11.8, 
6.5 and 11% in the levels of MCF-7, MDA-MB-231 and 
SK-BR-3 cells in the G0/G1 phase of the cell cycle and an 
increase of 6.5, 4.2 and 3.3% in the levels of MCF-7, MDA-
MB-231 and SK-BR-3 cells in the G0/G1 phase of the cell 
cycle were observed after 10 µM UA and 10 µM BA treat-
ments, respectively (Fig. 1b). UA- and BA-mediated effects 
on selected cell cycle inhibitors, namely p53, p21 and p27 
were then studied (Fig. 1c). Both triterpenotids caused an 
increase in p53 levels in MCF-7 cells (wild type p53) and 
exerted minimal effect on p53 levels in MDA-MB-231 
and SK-BR-3 cells (mutant p53) (Fig. 1c). In contrast, an 
increase in p21 levels in all cells examined was noticed 
(Fig. 1c). Except of UA-treated MCF-7 and SK-BR-3 cells, 
treatments with UA and BA did not significantly affect the 
levels of p27 (Fig. 1c). 24 h stimulation with 5 and 10 µM 
UA and BA also resulted in senescence-associated beta-
galactosidase (SA-β-gal) activity after 7 days of UA and 
BA removal (Fig.  1d). Higher levels of SA-β-gal positive 
cells were observed after UA treatment than after BA treat-
ment (Fig. 1d). The most potent effect was observed after 
treatment with 5 µM UA that resulted in 2.77-, 2.76- and 
4.29-fold increase in SA-β-gal positive MCF-7, MDA-
MB-231 and SK-BR-3 cells compared to untreated con-
trols, respectively (Fig. 1d).
UA induces apoptosis in breast cancer cells
We also evaluated if UA and BA may induce apoptotic cell 
death in breast cancer cells (Figs. 2, 3). Three markers of 
apoptosis were considered, namely phosphatidylserine 
externalization (Fig. 2) and multicaspase and mitopotential 
assays (Fig. 3).
UA (20  µM) promoted phosphatidylserine externaliza-
tion that was more accented in MDA-MB-231 (45.48% of 
cells) and SK-BR-3 cells (44.86% of cells) than in MCF-7 
cells (27.21% of cells) (Fig.  2). In contrast, BA did not 
induce significantly phosphatidylserine externalization 
(Fig. 2). We have also analyzed if UA pro-apoptotic action 
is specific to breast cancer cells and found that neither UA 
nor BA stimulated phosphatidylserine externalization in 
normal human mammary epithelial cells (HMEC) (Fig. 2). 
Elevation in pan caspase activity (the activity of multiple 
caspases, namely caspase 1, 3, 4, 5, 6, 7, 8 and 9) and depo-
larization of mitochondrial membrane potential (MMP) 
were also observed in 20  µM UA-treated breast cancer 
cells and again the effects were more pronounced in MDA-
MB-231 cells (46.01% of cells with multicaspase activity, 
41.93% of cells with depolarized MMP) and SK-BR-3 cells 
(54.38% of cells with multicaspase activity, 42.7% of cells 
with depolarized MMP) than in MCF-7 cells (13.17% of 
cells with multicaspase activity, 24.56% of cells with depo-
larized MMP) (Fig.  3). Three cancer cell lines positively 
responded to hydrogen peroxide, a pro-apoptotic stimu-
lus, with similar level of cells with multicaspase activ-
ity (Fig.  3a). In contrast, BA caused an elevation in mul-
ticaspase activity exclusively in SK-BR-3 cells (23.46% of 
cells). Perhaps, BA may promote other than apoptotic cell 
death in breast cancer cells as 20 µM BA treatment resulted 
in a minor increase in the levels of non-apoptotic dead cells 
(Fig. 3b).
UA- and BA-mediated autophagy
As autophagy may be considered both cytoprotective and 
cytotoxic phenomenon inhibiting and promoting cancer 
cell death, respectively, we have investigated if autophagy 
may be also induced in UA- and BA-treated cells using 
flow cytometry and LC3 antibody (Fig. 4).
In general, UA treatment resulted in autophagy induc-
tion in a concentration-dependent manner, whereas the 
Fig. 1  UA- and BA-induced cytotoxicity (a), changes in the cell 
cycle and cell cycle inhibitors (b, c) and stress-induced premature 
senescence (SIPS) (d) in breast cancer cells. a MTT assay. Metabolic 
activity at standard growth conditions is considered as 100%. The 
effect of solvent used (0.1% DMSO) is also presented. Bars indicate 
SD, n = 5, ***p < 0.001, **p < 0.01, *p < 0.05 compared to the control 
(ANOVA and Dunnett’s a posteriori test). b The percentage of cells 
in the G0/G1, S and G2/M phases of cell cycle was assessed using 
Muse™ Cell Analyzer and Muse™ Cell Cycle Kit. Representative 
histograms are shown. c Western blot analysis of the levels of p21, 
p27 and p53 cell cycle inhibitors. Anti-β-actin antibody was used as a 
loading control. The data represent the relative density normalized to 
β-actin. d Senescence-associated β-galactosidase (SA-β-gal) activity. 
Bars indicate SD, n = 3, ***p < 0.001, **p < 0.01, *p < 0.05 compared 
to the control (ANOVA and Dunnett’s a posteriori test). UA ursolic 




effect of BA was more or less evident (Fig. 4). The high-
est autophagy induction ratio of 2.5 and 2.1 in MDA-
MB-231 and SK-BR-3 cells after 20 µM UA treatment cor-
related with elevated apoptosis in these cells (Figs.  2, 3). 
Surprisingly, breast cancer cells differently responded to 
EBSS incubation (starvation-mediated autophagy) (Fig. 4). 
Autophagy induction ratio was 2.0, 3.2 and 1.1 in MCF-
7, MDA-MB-231 and SK-BR-3 cells, respectively (Fig. 4) 
that may reflect different susceptibility to autophagy induc-
tion in these cells.
UA- and BA-mediated oxidative and nitrosative stress
UA and BA provoked redox imbalance in all breast cancer 
cells examined (Fig. 5a).
UA-induced elevation in total reactive oxygen species 
(ROS), total superoxide and mitochondrial superoxide 
production was more potent than BA-mediated oxidative 
stress (Fig.  5a). Moreover, UA promoted protein carbon-
ylation and SK-BR-3 cells were the most susceptible to 
protein carbonylation, whereas BA did not induce protein 
carbonylation (Fig. 5b). 20 µM UA treatment resulted in an 
increase in nitric oxide levels that was the most pronounced 
in SK-BR-3 cells (Fig.  5c). Three cancer cell lines posi-
tively responded to stimulation with a nitric oxide donor, 
MAHMA NONOate with a comparable increase in the lev-
els of nitric oxide (Fig. 5c).
UA- and BA-induced DNA damage
UA and BA promoted DNA breaks, and DNA double 
strand breaks (DSBs) were more accented than DNA single 
strand breaks (SSBs) after treatments with two pentacyclic 
triterpenotids (Fig. 6a). UA was found to be a more potent 
inducer of DNA breaks than BA (Fig. 6a).
MDA-MB-231 cells were the most sensitive to UA-
mediated DNA breaks (Fig. 6a). UA-induced DNA breaks 
were accompanied by increased phosphorylation of ATM 
(ATM activation) but not by H2AX phosphorylation 
(γH2AX) (Fig.  6b). Moreover, 53BP1 foci formation was 
only observed after 20  µM UA treatment in MCF-7 cells 
(Fig. 6c). Etoposide treatment (a positive control for DNA 
damage induction) resulted in an elevation in DNA breaks 
and activation of DNA damage response (DDR) with 
increased phosphorylation of both ATM and H2AX in 
three breast cancer cells examined (Fig. 6a, b).
Fig. 2  UA- and BA-induced apoptosis in breast cancer cells (part I). 
Annexin V staining. Muse™ Cell Analyzer and Muse™ Annexin V 
and Dead Cell Assay Kit (Merck Millipore) were used. UA and BA 
did not promote apoptosis in normal human mammary epithelial cells 




UA- and BA-mediated changes in glycolytic pathway
We have then analyzed if increased cytotoxic action of 
20  µM UA resulted in cytotoxic autophagy and apoptotic 
cell death in breast cancer cells may be associated with 
affected glycolysis and related signaling pathways (Fig. 7).
Indeed, treatment with 20 µM UA caused a decrease 
in intracellular ATP and lactate pools (Fig.  7a, b). The 
levels of ATP were diminished of 34, 25 and 40% in 
MCF-7, MDA-MB-231 and SK-BR-3 cells compared to 
untreated controls, respectively (Fig.  7a) and the levels 
of intracellular lactate were decreased of 64 and 85% 
in MCF-7 and SK-BR-3 cells compared to untreated 
controls, respectively (Fig.  7b). The lactate levels in 
MDA-MB-231 cells were fourfold lower compared to 
MCF-7 and SK-BR-3 cells in steady state and did not 
change after UA and BA treatments (Fig.  7b). In gen-
eral, BA treatment did not result in changes in ATP and 
lactate levels, except of 20  µM BA-mediated decrease 
in lactate levels in SK-BR-3 cells (Fig. 7a, b). UA treat-
ment caused a decrease in the levels of hexokinase HK2 
in MDA-MB-231 and SK-BR-3 cells (Fig. 7c). UA treat-
ment also caused a decrease in the levels of pyruvate 
kinase PKM2 in all three breast cancer cells (Fig.  7c). 
There were no significant changes in the levels of glu-
cose transporter GLUT1 and lactate dehydrogenase 
LDHA in UA-treated cancer cells (Fig.  7c). At the 
concentration of 20 µM UA, a decrease in the levels of 
Fig. 3  UA- and BA-induced apoptosis in breast cancer cells (part II). 
Multicaspase assay (a) and mitopotential assay (b). a Muse™ Cell 
Analyzer and Muse™ Multi-caspase Assay Kit were used. 30  min 
treatment with 10 mM hydrogen peroxide (HP) served as a positive 
control (C+). b Muse™ Cell Analyzer and Muse™ Mitopotential 
Assay Kit were used. UA ursolic acid, BA betulinic acid
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Fig. 4  UA- and BA-induced 
autophagy in breast cancer 
cells. Autophagy was measured 
using Muse™ Cell Analyzer 
and Muse™ Autophagy LC3-
antibody based Kit (Merck Mil-
lipore). As a positive control, 
cells were incubated in EBSS 
at 37 °C for 6 h. Autophagy 
induction ratio (test sample 
fluorescence, red histogram, vs. 
control sample fluorescence, 
gray histogram) is presented. 
UA ursolic acid, BA betulinic 
acid. (Color figure online)
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phosphorylated form of AKT, protein kinase B regulat-
ing glucose metabolism, was also observed in all three 
breast cancer cells (Fig.  7c). UA-mediated decrease in 
ATP pools promoting cellular energy stress resulted in 
the activation of AMPK (an increase in phosphorylated 
form of AMPK) in all three breast cancer cells (Fig. 7c). 
Except of BA-mediated decrease in lactate and PKM2 
levels in SK-BR-3 cells, and BA-mediated decrease in 
HK2 and PKM2 levels in MCF-7 cells, BA did not pro-
voke significant changes in glycolytic pathway in breast 
cancer cells (Fig. 7).
UA-induced inhibition of ERK pathway
We have then analyzed if 20  µM UA-induced autophagy 
and apoptosis may be also associated with decreased pro-
survival signal of phospho-ERK1/2 (Fig. 8).
As we have used three different breast cancer cell lines, 
first, we have compared steady state levels of phosphoryl-
ated form of ERK1/2 in three cell populations and found 
that MCF-7 cells are 92.2% phospho-ERK1/2-negative, 
MDA-MB-231 cells are 89.7% phospho-ERK1/2-positive 
and SK-BR-3 cells are 49.7% phospho-ERK1/2-positive in 
the control conditions (Fig. 8). Upon 20 µM UA treatment, 
the levels of phospho-ERK1/2-positive cells decreased 
Fig. 5  UA- and BA-mediated oxidative (a, b) and nitrosative (c) 
stress in breast cancer cells. a Total reactive oxygen species (ROS) 
production, total superoxide production and mitochondrial super-
oxide production were assessed using CM-H2DCF-DA, DHE and 
MitoSOX fluorogenic probes, respectively. Bars indicate SD, n = 5, 
***p < 0.001, **p < 0.01, *p < 0.05 compared to the control (ANOVA 
and Dunnett’s a posteriori test). b Protein carbonylation was revealed 
using 2,4-dinitrophenylhydrazine (DNPH) derivatization and anti-
DNP antibody (OxyBlot™ Protein Oxidation Detection Kit, Merck 
Millipore). A positive control with a mixture of standard proteins 
with attached DNP residues (lane M) is also shown. c Nitric oxide 
levels were measured using Muse™ Cell Analyzer and Muse™ Nitric 
Oxide Kit (Merck Millipore). As a positive control, cells were treated 
for 5 min with a nitric oxide donor, namely 1 mM MAHMA NONO-




in MDA-MB-231 and SK-BR-3 cells to 58.3 and 26.2%, 
respectively (Fig. 8). In contrast, a similar decrease in phos-
pho-ERK1/2-positive cells in MDA-MB-231 and SK-BR-3 
cells was not observed after 20 µM BA treatment (Fig. 8). 
At lower non-apoptotic concentrations of UA (5 and 
10 µM), an increase in phospho-ERK1/2-positive cells was 
revealed in MCF-7 and SK-BR-3 cells to 31.8 and 69.6% of 
phospho-ERK1/2-positive cells, respectively (Fig. 8).
Discussion
Anticancer activity of two pentacyclic triterpenoids, ursolic 
acid (UA) and betulinic acid (BA), against three breast can-
cer cells of different receptor status, namely MCF-7  (ER+, 
 PR+/−,  HER2−), MDA-MB-231  (ER−,  PR−,  HER2−) and 
SK-BR-3  (ER−,  PR−,  HER2+) was compared and a bipha-
sic response was revealed (Fig. 9).
UA and BA, when used at the concentrations of 5 and 
10  µM, caused p21-mediated G0/G1 cell cycle arrest and 
stress-induced premature senescence (SIPS). UA (20 µM), 
but not BA (20 µM), provoked changes in glycolytic path-
way and energy stress that resulted in cytotoxic autophagy 
and apoptotic cell death.
To the best of our knowledge, this is the first study on 
UA- and BA-induced senescence in cancer cells. More 
recently, 20 µM BA-mediated senescence in human immor-
talized keratinocyte cell line HaCaT was reported as 
judged by increased levels of senescence associated-beta-
galactosidase (SA-β-gal) positive cells that was triggered 
by destabilized lipid bilayers and damaged mitochondrial 
Fig. 6  UA- and BA-induced DNA damage (a) and DNA damage 
response (b, c) in breast cancer cells. a Comet assay. DNA double 
strand breaks (DSBs) (neutral comet assay) and DNA single strand 
breaks (SSBs) (alkaline comet assay) are presented. The percentage 
of tail DNA was used as a parameter of DNA damage. Bars indicate 
SD, n = 150, *p < 0.05, **p < 0.01, ***p < 0.001 compared to the con-
trol (ANOVA and Dunnett’s a posteriori test). b pATM and pH2AX 
(γH2AX) (the activation of ATM and H2AX) were measured using 
Muse™ Cell Analyzer and Muse™ Multi-Color DNA Damage Kit 
(Merck Millipore). As a positive control for DNA damage, 24 h treat-
ment with 10  µM etoposide was used (C+). c 53BP1 foci forma-
tion was revealed using 53BP1 immunostaining and calculated per 
nucleus. Box and whisker plots are shown, n = 100, ***p < 0.001 com-
pared to the control (ANOVA and Dunnett’s a posteriori test). UA 
ursolic acid, BA betulinic acid
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Fig. 7  UA- and BA-mediated 
changes in glycolysis and 
related signaling pathways. a 
ATP levels. Bars indicate SD, 
n = 3, ***p < 0.001, *p < 0.05 
compared to the control 
(ANOVA and Dunnett’s a 
posteriori test). b Lactate 
levels. Bars indicate SD, n = 3, 
***p < 0.001 compared to the 
control (ANOVA and Dunnett’s 
a posteriori test). c Western 
blot analysis of GLUT1, HK2, 
PKM2, LDHA, AKT, pAKT, 
AMPK and pAMPK levels. 
Anti-β-actin antibody was used 
as a loading control. The data 
represent the relative density 
normalized to β-actin. UA urso-
lic acid, BA betulinic acid
 Apoptosis
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Fig. 8  UA- and BA-mediated 
ERK1/2 activity in breast can-
cer cells. ERK1/2 activity was 
measured using Muse™ Cell 
Analyzer and Muse™ MAPK 
Activation Dual Detection Kit 
(Merck Millipore). UA ursolic 
acid, BA betulinic acid
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and lysosomal membranes [21]. We were able to observe 
cytostatic action of UA and BA against breast cancer cells 
at much lower concentrations and UA was found to pos-
sess a more potent pro-senescent activity than BA. The 
magnitude of G0/G1 cell cycle arrest and an elevation in 
p21, the cyclin-dependent kinase inhibitor, correlated with 
increased SA-β-gal staining in UA-treated cells compared 
to BA-treated cells, all of which are classical biomarkers of 
senescence [22, 23]. In general, p21 may be activated by 
both p53-dependent or p53-independent mechanisms [24]. 
Treatments with UA and BA also resulted in upregulation 
of p53 in MCF-7 cells with wild type p53 [25]. Involve-
ment of p53-dependent pathway in UA-mediated p21 
induction has already been postulated [26]. Knockdown 
of p53 abolished UA-mediated G0/G1 cell cycle arrest 
and prevented p21 induction in MCF-7 cells [26]. How-
ever, UA- and BA-mediated upregulation of p21 was also 
observed in MDA-MB-231 and SK-BR-3 cells with mutant 
p53 [25], thus active p53 is not required for UA- and 
BA-induced activation of p21 and cellular senescence in 
breast cancer cells.
UA at the concentration of 20 µM specifically induced 
apoptotic cell death in breast cancer cells of different recep-
tor status (phosphatidylserine externalization, multicas-
pase activity, depolarization of mitochondrial membrane 
potential). However, pro-apoptotic effects of UA in MCF-7 
cells were slightly less accented than in MDA-MB-231 
and SK-BR-3 cells. MCF-7 cells are caspase 3-deficient 
as a result of a deletion mutation in exon 3 of the CASP3 
gene [27] and recovery of caspase 3 activity may poten-
tially sensitize MCF-7 cells to anticancer drug treatment, 
e.g., doxorubicin and etoposide [28]. However, MCF-7 
cells are still sensitive to pro-apoptotic stimuli, e.g., tumor 
necrosis factor (TNF)- or staurosporine-induced apop-
tosis [27], and Bax-induced apoptosis [29], but this was 
not accompanied by DNA fragmentation [27, 29]. During 
Bax-induced apoptosis, caspase 6 activation, augmented 
levels of poly(ADP-ribose) polymerase cleavage and lamin 
B cleavage were observed in MCF-7 cells [29]. Perhaps, 
caspase 3 is not essential to trigger apoptosis in MCF-7 
cells. Pro-apoptotic effects of UA on breast cancer cells 
have been already investigated but much higher concentra-
tions were used [30–32]. UA (53  µM) induced apoptosis 
by Bcl-2 downregulation in MCF-7 cells [30]. UA (30 µM) 
also promoted apoptosis by suppressing the expression of 
transcription factor FoxM1 that lowered cyclin D1/CDK4 
expression in MCF-7 cells [31]. UA (40 µM) induced apop-
tosis through both mitochondrial death pathway and extrin-
sic death receptor pathway in MDA-MB-231 cells [32]. 
However, the mechanisms of anti-proliferative and pro-
apoptotic action of UA are not fully elucidated.
We found that UA disrupted cancer cell redox homeo-
stasis by increasing production of total reactive oxygen spe-
cies (ROS), total superoxide and mitochondrial superoxide 
that resulted in protein carbonylation even at non-apoptotic 
concentrations used. Moreover, at the concentration of 
20 µM that promoted apoptosis, UA increased nitric oxide 
levels. In general, UA is considered to be an antioxidant 
[33–35] and data on its pro-oxidative action are limited 
[36, 37]. It has been reported that UA-induced apoptosis 
in MG-63 osteosarcoma cells and UA-induced autophagy 
in U87MG glioma cells were accompanied by oxidative 
stress [36, 37]. ROS may be considered as a double-edged 
sword for cancer cells [38]. Moderate levels of ROS are 
required for cancer growth and proliferation [38, 39]. ROS 
are also implicated in cancer angiogenesis, invasion and 
metastasis [40–42]. However, high levels of ROS may pro-
mote oxidative damage and cell death [38]. Elevated pro-
duction of ROS may also affect mitochondrial membrane 
potential leading to apoptotic cell death [43, 44]. Indeed, 
UA-mediated oxidative stress resulted in depolarization of 
Fig. 9  UA-induced and oxidative stress-mediated biphasic response 
in breast cancer cells. At lower concentrations (5 and 10  µM), UA 
promoted p21-mediated cell cycle arrest and stress-induced prema-
ture senescence (SIPS), whereas 20  µM UA caused AKT-mediated 
changes in glycolytic pathway leading to energy stress, cytotoxic 
autophagy and apoptosis in breast cancer cells. UA-induced apop-
tosis was accompanied by increased nitric oxide levels, pATM and 




mitochondrial membrane potential and apoptosis in breast 
cancer cells.
UA-induced ROS may affect the activity of protein 
kinases involved in cell signaling pathways regulating 
cell proliferation and cell survival, such as AKT, AMPK, 
ERK1/2 and ATM (this study). 20  µM UA inhibited the 
activity of AKT that resulted in decreased levels of key gly-
colytic enzymes, such as hexokinase (HK2) and pyruvate 
kinase (PKM2), and subsequently caused a decrease in ATP 
and lactate pools in breast cancer cells. AKT is frequently 
hiperactivated in cancer cells and stimulates glycolysis by 
increasing the expression and membrane translocation of 
glucose transporters and by phosphorylation of hexokinase 
and phosphofructokinase 2, thus promoting cell prolifera-
tion [7, 45]. UA-mediated inhibition of AKT signaling has 
already been shown to promote the suppression of cell pro-
liferation and apoptosis in SW480 and LoVo colon cancer 
cells [46] and K562 leukemia cells [47]. More recently, UA 
derivatives have been developed and tested with 2-deoxy-
d-glucose (2-DG) for suppression of cancer cell glucose 
metabolism [48, 49]. Combined treatment resulted in a 
synergistic inhibition of glycolysis and apoptosis induc-
tion in various cancer cells both in vitro and in vivo [48, 
49]. UA-mediated ATP depletion induces energy stress that 
resulted in AMP-activated protein kinase (AMPK) activa-
tion in breast cancer cells that in turn promoted cytotoxic 
autophagy and apoptosis (this study). UA-induced AMPK 
activation also contributed to growth inhibition and apop-
tosis in T24 bladder cancer cells [50] and hepatoma HepG2 
cells [51, 52], and autophagy in U87MG glioma cells [37]. 
More recently, AMPK was found to be a negative regula-
tor of aerobic glycolysis and a suppressor of tumor growth 
in  vivo [53]. UA-induced AMPK activation may be also 
mediated by UA-associated oxidative and nitrosative stress 
(this study). It has been reported that reactive oxygen spe-
cies and reactive nitrogen species may activate AMPK 
[54–56]. Nitric oxide may also activate ataxia telangiecta-
sia mutated (ATM) kinase, DNA damage response kinase 
[57], that in turn activate AMPK and promote cytotoxic 
autophagy in MCF-7 cells [58]. ATM may be also activated 
directly by ROS [59]. UA induced DNA damage in breast 
cancer cells and this was accompanied by phosphorylation 
of ATM but not by phosphorylation of H2AX and 53BP 
foci formation (this study). Perhaps, UA-mediated ATM 
activation is a part of prodeath response to UA-induced 
oxidative and nitrosative stress rather than classical DNA 
damage response (DDR). UA-mediated apoptosis was also 
associated with decreased phosphorylation of extracellular 
signal-regulated kinase 1 and 2 (ERK1/2) in breast can-
cer cells. Our data are in agreement with previously pub-
lished results on UA-mediated inhibition of ERK pathway 
and apoptosis induction in SW480 and LoVo colon cancer 
cells [46]. ERKs are multifunctional kinases involved in the 
regulation of cell cycle, cell proliferation and survival, cell 
migration, angiogenesis and cell death [60–62]. ERK1/2 
may also promote the Warburg effect by phosphorylating 
pyruvate kinase M2 that lead to nuclear PKM2-mediated 
upregulation of GLUT1 and LDHA [63]. ERK may be also 
implicated in a cross-talk between apoptosis and autophagy 
[64].
Autophagy, a stress adaptation, may result in both cell 
survival and cell death that depends on magnitude and cell 
context [65]. However, it has been proposed that four func-
tional forms of autophagy may be induced as a response to 
stress induced by chemotherapy or radiation, namely cyto-
protective autophagy that promotes cell survival, cytotoxic 
autophagy that results in cell death, cytostatic autophagy 
that causes growth arrest and non-protective autophagy 
with no contribution to cell death or survival [66]. In our 
experimental conditions, 20  µM UA-induced autophagy 
was accompanied by elevated apoptosis and 20 µM BA, a 
mild inducer of autophagy did not provoke apoptotic cell 
death in breast cancer cells. Data on effects of UA-induced 
autophagy in breast cancer cells are limited [67]. It has been 
reported that 20 µM UA induced cytoprotective autophagy 
that compromised UA-mediated apoptosis in MCF-7 cells 
[67]. However, the authors used much higher cell densi-
ties for treatment with UA than used in the present study 
that may reflect different cell response [67]. Cytoprotective 
autophagy achieved by upregulation of MCL1, antiapop-
totic protein and a member of Bcl-2 family, acted at narrow 
concentration window of UA (15–20 µM) and at the con-
centrations higher than 20 µM (25–30 µM) apoptosis was 
elevated [67]. UA promoted cytotoxic autophagy in HCT15 
colorectal cancer cells [68] and TC-1 cervical cancer cells 
[69]. In contrast, autophagy served as a survival mecha-
nism in PC3 prostate cancer cells against UA-induced 
apoptosis [70].
In summary, we have shown that UA- and BA-medi-
ated oxidative stress may lead to p21-associated G0/G1 
cell cycle arrest and stress-induced premature senescence 
in breast cancer cells, when used at the concentrations of 
5 and 10 µM (Fig. 9). At the concentration of 20 µM, UA 
promoted combined autophagy and apoptosis by AKT 
inhibition-mediated changes in glycolytic pathway lead-
ing to energy stress and AMPK activation (Fig. 9). 20 µM 
UA also caused an elevation in nitric oxide levels and ATM 
activation, however, without classical DDR response with 
53BP1 foci formation. UA-induced apoptosis may also be 
mediated by decreased phospho-ERK1/2 signals and depo-
larization of mitochondrial membrane potential. Taken 
together, UA-induced changes in glycolytic pathway lead-
ing to cytotoxic autophagy and apoptotic cell death may be 
considered as an attractive anticancer strategy.
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